This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Soltész, P Articles by Szegedi, G Search for Related Content PubMed PubMed Citation Articles by Soltész, P Articles by Szegedi, G Social Bookmarking                         What's this?

Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients

Third Department of Medicine, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary

K Veres

Third Department of Medicine, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary

G Lakos

Third Department of Medicine, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary, lakos{at}iiibel.dote.hu

E Kiss

Third Department of Medicine, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary

L Muszbek

Institute of Clinical Biochemistry and Molecular Pathology, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary

G Szegedi

Third Department of Medicine, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary

We retrospectively analysed the data of 1519 antiphospholipid antibody (APLA) positive patients between 1986 and 1999. Among them 637 were considered to have antiphospholipid syndrome (APS) based on the 1999 preliminary classification criteria, while 704 patients had no clinical signs of the syndrome. Our aim was to compare the autoantibody profile and clinical characteristics of primary and secondary APS, moreover to evaluate the associations between different APLA and specific symptoms attributable to APS. In our results, the APLA profiles for primary and SLE-associated secondary APS were similar. Among the evaluated clinical symptoms, cerebrovascular thrombosis was found to be more frequent in the SLE-associated, than in the primary APS group (P = 0.04). We identified important differences in the clinical profile of patient populations with various types of APLA. Venous thrombosis occurred more frequently in subjects with lupus anticoagulant (LA), than in those with IgG or IgM type ACLA (P < 0.0001), while coronary, carotid and peripheral artery thrombosis occurred more often in subjects with IgG or IgM ACLA (P < 0.0001). These findings may support the role of antibodies to cardiolipin or its cofactor, b2glycoprotein I (b2-GPI) in the initiation and progression of atherosclerosis. Cerebrovascular thrombosis was detected in larger proportion of LA or IgG ACLA-positive patients compared with to IgM ACLA-positive subjects, while the occurrence of foetal loss was similar in all three groups.

Key Words: consensus criteria • anticardiolipin antibodies • lupus anticoagulant • primary APS • secondary APS

Lupus, Vol. 12, No. 4, 302-307 (2003)
DOI: 10.1191/0961203303lu339oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. DANOWSKI, M. N. L. de AZEVEDO, J. A. de SOUZA PAPI, and M. PETRI Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus J Rheumatol, June 1, 2009; 36(6): 1195 - 1199. [Abstract] [Full Text] [PDF]

				C Lopez-Pedrera, N Barbarroja, M. Aguirre, L. Torres, F Velasco, and M. Cuadrado Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases Lupus, October 1, 2008; 17(10): 905 - 916. [Abstract] [PDF]

				T. Tarr, G. Lakos, H.P. Bhattoa, G. Szegedi, Y. Shoenfeld, and E. Kiss Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus Lupus, May 1, 2007; 16(5): 324 - 328. [Abstract] [PDF]

				T Tarr, G Lakos, H P Bhattoa, Y Shoenfeld, G Szegedi, and E Kiss Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients Lupus, January 1, 2007; 16(1): 39 - 45. [Abstract] [PDF]

				Z Szekanecz and Y Shoenfeld Lupus and cardiovascular disease: the facts Lupus, November 1, 2006; 15(11_suppl): 3 - 10. [Abstract] [PDF]

				Y. Shoenfeld, R. Gerli, A. Doria, E. Matsuura, M. M. Cerinic, N. Ronda, L. J. Jara, M. Abu-Shakra, P. L. Meroni, and Y. Sherer Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases Circulation, November 22, 2005; 112(21): 3337 - 3347. [Full Text] [PDF]

				J. A. Gomez-Puerta, R. Cervera, L. M. Calvo, B. Gomez-Anson, G. Espinosa, G. Claver, S. Bucciarelli, A. Bove, M. Ramos-Casals, M. Ingelmo, et al. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients Rheumatology, January 1, 2005; 44(1): 95 - 99. [Abstract] [Full Text] [PDF]

				K Veres, G Lakos, A Kerenyi, Z Szekanecz, G Szegedi, Y Shoenfeld, and P Soltesz Antiphospholipid antibodies in acute coronary syndrome Lupus, June 1, 2004; 13(6): 423 - 427. [Abstract] [PDF]